HAI Book 2025 - Flipbook - Page 711
Kac, Przemyslaw
Association of CSF P-tau and MTBR-Tau biomarkers with amyloid and tau
PET
Przemyslaw Kac1, Federica Ribaldi2,3, Nicholas J. Ashton1,4,5,6, Augusto J. Mendes2,3, Hlin
Kvartsberg7, Aurélien Lathuiliere2,3, Michael Turton8, Chen Wang2,3, Peter Harrison8, Henrik
Zetterberg1,7,9,10,11,12, Thomas K. Karikari1,13, Valentina Garibotto14,15,16, Kaj Blennow1,7,17,18, Giovanni
B. Frisoni2,3
1
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy
at University of Gothenburg, Mölndal, SE
2
Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, CH
3
Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, CH
4
Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, NO
5
NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London &
Maudsley NHS Foundation, London, GB
6
Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London,
London, GB
7
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, SE
8
Bioventix Plc, Farnham, GB
9
Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health,
University of Wisconsin-Madison, Madison, WI, US
10
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, CN
11
Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London,
London, GB
12
UK Dementia Research Institute, University College London, London, GB
13
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, US
14
Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and
Faculty of Medicine, University of Geneva, Geneva, CH
15
Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, CH
16
CIBM Center for Biomedical Imaging, Geneva, CH
17
Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, FR
18
Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of
Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated
Hospital of USTC, Hefei, CN
Background: Phosphorylated-tau (p-tau) and microtubule-binding region tau biomarkers (MTBR-Tau) CSF
biomarkers for Alzheimer9s disease have been included as core biomarkers in the newly revised criteria for
diagnosis and staging of Alzheimer's disease. While immunoassays targeting n-terminal (p-tau181, p-tau217, ptau231) also have associations with amyloid beta, MTBR-tau is associated mostly with tau pathology. In this study,
we have included immunoassays targeting core soluble n-terminal biomarkers 3 p-tau181, p-tau217, and p-tau231,
together with developed and validated immunoassays for p-tau212 and MTBR-Tau368, to assess their level in
healthy controls, MCI and AD cases from memory clinic.
Methods: In-house developed CSF p-tau181, p-tau212, p-tau217, p-tau231, and MTBR-Tau368 Single molecule array
(Simoa) immunoassays were used to measure levels of the biomarkers in Geneva Memory Center (N=112
participants; CU (N=49) MCI (N=55) Dementia (N=8). Amyloid-PET images were acquired using 18F-florbetapir or
18F-flutemetamol tracers, while tau-PET images were acquired using 18F-flortaucipir. Amyloid-PET (A +) and tauPET (T +) positivity were assessed visually by an expert in nuclear medicine (VG).
Results: We observe a significant correlation of p-tau biomarkers with the CSF AB42/40 ratio. On the contrary,
HAI2025 - 711
